Bevacizumab biosimilar (Sinocelltech)

贝伐珠单抗生物类似药（神州细胞）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBevacizumab biosimilar (Sinocelltech)
Drug Alias Name贝伐珠单抗生物仿制药（神州细胞工程）贝伐人源化单抗生物类似药（神州细胞工程）贝伐人源化单抗生物仿制药（神州细胞工程）贝伐单抗生物仿制药（神州细胞工程）贝伐单抗生物类似药（神州细胞工程） +[10] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular DegenerationUterine Cervical Neoplasms +[11] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Approved Indications in ChinaUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinoCelltech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationUterine Cervical NeoplasmsFallopian Tube Neoplasms +[9] 
Inactive IndicationsMacular DegenerationCarcinoma, Ovarian Epithelial

Other Information

ATC CodeN/A
Related LinksN/A